SECISBP2L

Across TCGA pan-cancer cohorts, SECISBP2L Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SECISBP2L data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SECISBP2L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SECISBP2L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and KICH are the cancer types where SECISBP2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.293	0.753	<.001	25	view →
UCEC	DFS	Median	All	0.981	0.822	.002	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
STAD	OS	Median	IV	0.074	0.496	.002	12	view →
HNSC	OS	Median	III,IV	0.250	0.678	.010	9	view →
SKCM	OS	Median	IV	0.415	0.861	.014	8	view →
COAD	OS	Median	III,IV	0.183	0.696	.049	3	view →
KIRC	OS	Median	All	0.299	0.633	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SECISBP2L–LUSC (DFS)

Open the LUSC breakdown →